Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022 , 14, 4265

Cancers (Basel). 2022 Dec 14;14(24):6160. doi: 10.3390/cancers14246160.

Matteo Ponzo¹, Anais Debesset¹, Mélissande Cossutta¹, Mounira Chalabi-Dchar², Claire Houppe¹, Caroline Pilon^{1

3}, Alba Nicolas-Boluda⁴, Sylvain Meunier¹, Fabio Raineri¹, Allan Thiolat¹, Rémy Nicolle⁵, Federica Maione^{6

7}, Serena Brundu^{6

7}, Carina Florina Cojocaru^{6

7}, Philippe Bouvet^{4

8}, Corinne Bousquet⁹, Florence Gazeau³, Christophe Tournigand^{1

10}, José Courty^{1

2}, Enrico Giraudo^{6

7}, José L Cohen^{1

3}, Ilaria Cascone^{1

3}

¹ Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France.
² Cancer Research Center of Lyon, Cancer Cell Plasticity Department, University of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, F-69008 Lyon, France.
³ AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre D'investigation Clinique Biothérapie, F-94010 Créteil, France.
⁴ Matières et Systèmes Complexes (MSC), Université de Paris, CNRS UMR 7057, F-75006 Paris, France.
⁵ Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, F-75013 Paris, France.
⁶ Laboratory of Tumor Microenvironment, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
⁷ Department of Science and Drug Technology, University of Torino, 10125 Torino, Italy.
⁸ Ecole Normale Supérieure de Lyon, University of Lyon, F-69342 Lyon, France.
⁹ UMR INSERM-1037, Cancer Research Center of Toulouse (CRCT), Toulouse University III, F-31037 Toulouse, France.
¹⁰ AP-HP, Service d'Oncologie Médicale, Groupe Hospitalo-Universitaire Chenevier Mondor, F-94010 Créteil, France.

Abstract